SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. (SABS) is a healthcare company (biotechnology) based in the United States. The share price is $2.94, down 2.00% on the day, which values the company at $264.86M. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$2.94−2.00% today
Market value
$264.86M
200-week average
$4.3332% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

SAB Biotherapeutics, Inc. in more detail

SABS trades at -3.1× next year's expected earnings. It sits 32% below its 200-week average of $4.33.

In its favour: More cash than debt. Worth checking: Share count keeps rising; Thin interest cover.

1 of the superinvestors tracked here hold SABS, including Peter Kolchinsky (0.1% of the portfolio).

Superinvestors holding SABS

1 of the investors tracked here report a position in their latest 13F filing.

SAB Biotherapeutics, Inc. (SABS): questions and answers

What is SAB Biotherapeutics, Inc.'s market cap?

SAB Biotherapeutics, Inc. is valued at $264.86M at a share price of $2.94.

Is SABS above its 200-week moving average?

No. SABS is 32.1% below its 200-week average of $4.33. Long-term investors watch that line because strong companies rarely trade below it for long.

Does SABS pay a dividend?

SAB Biotherapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own SABS?

In their latest quarterly filings, Peter Kolchinsky (0.1% of the portfolio) hold SABS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “SAB Biotherapeutics, Inc. (SABS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SABS

Underlying data: Yahoo Finance; company filings with the SEC.